Back to Search Start Over

21 st Century Citizen Pharma: The FDA & Patient-Focused Product Development.

Authors :
Paradise J
Source :
American journal of law & medicine [Am J Law Med] 2018 May; Vol. 44 (2-3), pp. 309-327.
Publication Year :
2018

Abstract

Perpetual debate regarding the delicate balance between access and innovation and the protection of the public health and safety dominate discussions of the United States Food and Drug Administration ("FDA"). Established chiefly as a command and control federal administrative agency, iterative changes in legislation have shaped the FDA's activity in drug, biologic, and medical device regulation over the course of the last one hundred plus years. The most recent fundamental reframing of the agency's authority and directive presented itself in the 21 <superscript>st</superscript> Century Cures Act, reflecting an important role for patient perspectives in the regulatory process. This Article explores recent developments in patient-focused product development efforts at the FDA and offers modest insights on the increasing role of patients, and patient advocacy groups, in agency decision-making. The Article terms this era "21 <superscript>st</superscript> century citizen pharma."

Details

Language :
English
ISSN :
0098-8588
Volume :
44
Issue :
2-3
Database :
MEDLINE
Journal :
American journal of law & medicine
Publication Type :
Academic Journal
Accession number :
30106644
Full Text :
https://doi.org/10.1177/0098858818789426